ArticleKidney international reports2024

Design and Rationale of the Phase 2 Baricitinib Study in Apolipoprotein L1-Mediated Kidney Disease (JUSTICE).

Opeyemi A Olabisi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.